Needham analyst David Saxon downgrades Globus Medical (NYSE:GMED) from Buy to Hold.
Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon
Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc.